Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to assess the safety and pharmacokinetics of KP-1461
given every 12 hours for 14 days when administered to HIV+ patients who have failed multiple
highly active antiretroviral therapy (HAART) regimens. Patients currently on HAART will be
required to discontinue all HAART medications for up to 6 weeks after screening eligibility
has been determined.